A Study of DXC014 in Patients With Advanced Solid Tumors.

Summary

This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC014 in patients with Advanced Solid Tumors.

Timeline

Start

2026-03-03

Primary completion

2030-10-20

Completion

2030-10-20

Drugs

Indications